NL7909199A - Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan. - Google Patents
Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan. Download PDFInfo
- Publication number
- NL7909199A NL7909199A NL7909199A NL7909199A NL7909199A NL 7909199 A NL7909199 A NL 7909199A NL 7909199 A NL7909199 A NL 7909199A NL 7909199 A NL7909199 A NL 7909199A NL 7909199 A NL7909199 A NL 7909199A
- Authority
- NL
- Netherlands
- Prior art keywords
- thiazolidine
- carboxylic acid
- pharmaceutically acceptable
- acceptable salt
- agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 19
- 201000010099 disease Diseases 0.000 title claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 29
- 230000030944 contact inhibition Effects 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 239000008176 lyophilized powder Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000002254 cytotoxic agent Substances 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- -1 alkali metal salt Chemical class 0.000 claims description 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000000979 retarding effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 35
- 201000011510 cancer Diseases 0.000 description 23
- 238000011282 treatment Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 201000008827 tuberculosis Diseases 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 231100000065 noncytotoxic Toxicity 0.000 description 4
- 230000002020 noncytotoxic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 206010027458 Metastases to lung Diseases 0.000 description 3
- KUGRPPRAQNPSQD-UHFFFAOYSA-N OOOOO Chemical compound OOOOO KUGRPPRAQNPSQD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 201000003911 head and neck carcinoma Diseases 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000003804 salivary gland carcinoma Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100013460 Mus musculus Ftl2 gene Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004279 formaldehyde Drugs 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- CCOXWRVWKFVFDG-UHFFFAOYSA-N pyrimidine-2-carbaldehyde Chemical compound O=CC1=NC=CC=N1 CCOXWRVWKFVFDG-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/971,729 US4384001A (en) | 1978-12-21 | 1978-12-21 | Treatment of tumors with thiazolidine-4-carboxylic acid |
| US97172978 | 1978-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL7909199A true NL7909199A (nl) | 1980-06-24 |
Family
ID=25518727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL7909199A NL7909199A (nl) | 1978-12-21 | 1979-12-20 | Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4384001A (cs) |
| JP (1) | JPS55115822A (cs) |
| AU (1) | AU5390579A (cs) |
| BE (1) | BE880744A (cs) |
| CA (1) | CA1149284A (cs) |
| DE (1) | DE2951050A1 (cs) |
| DK (1) | DK542979A (cs) |
| ES (1) | ES487052A0 (cs) |
| FR (1) | FR2444459A1 (cs) |
| GB (1) | GB2039736B (cs) |
| IL (1) | IL58948A0 (cs) |
| IT (1) | IT1193348B (cs) |
| LU (1) | LU82013A1 (cs) |
| NL (1) | NL7909199A (cs) |
| SE (1) | SE7910300L (cs) |
| ZA (1) | ZA796918B (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE53332B1 (en) * | 1980-03-14 | 1988-10-26 | Efamol Ltd | Pharmaceutical compositions |
| JPS57128625A (en) * | 1981-01-30 | 1982-08-10 | Rikagaku Kenkyusho | Carcinostatic |
| US4335210A (en) * | 1981-02-11 | 1982-06-15 | Cornell Research Foundation | Method of producing L-cysteine |
| FR2547728B1 (fr) * | 1983-06-24 | 1986-05-02 | Riker Laboratories Inc | Medicament a base d'acide d thiazolidine carboxylique |
| FR2547729B1 (fr) * | 1983-06-24 | 1986-05-02 | Riker Laboratories Inc | Medicament a base d'acide dl thiazolidine carboxylique |
| DE3586683T2 (de) * | 1984-12-18 | 1993-04-08 | Clark Pharma Dev | Antitumorzusammensetzungen enthaltend ein reaktionsprodukt zwischen einem cytotoxischen aldehyd und penicillamin und deren verwendung zur herstellung von arzneimitteln. |
| JPH066578B2 (ja) * | 1985-12-27 | 1994-01-26 | 三共株式会社 | チアゾリジン誘導体 |
| JPH01170063U (cs) * | 1988-05-11 | 1989-11-30 | ||
| JPH0467539U (cs) * | 1990-10-18 | 1992-06-16 | ||
| DE69214467T3 (de) * | 1991-01-10 | 2000-09-28 | Transcend Therapeutics, Inc. | Verwendung von L-2-oxo Thiazolidin-4-carboxylat zur Behandlung von Atemnotsyndrom |
| PL181867B1 (pl) * | 1994-06-14 | 2001-09-28 | Dainippon Pharmaceutical Co | Nowe zwiazki, sposoby ich wytwarzania i srodki przeciw nowotworowe PL |
| ES2277787B1 (es) * | 2006-01-02 | 2008-06-16 | Universidad De Cadiz | Empleo de tioprolina en tratamientos de reduccion de peso corporal. |
-
1978
- 1978-12-21 US US05/971,729 patent/US4384001A/en not_active Expired - Lifetime
-
1979
- 1979-12-12 GB GB7942753A patent/GB2039736B/en not_active Expired
- 1979-12-13 IL IL58948A patent/IL58948A0/xx unknown
- 1979-12-14 SE SE7910300A patent/SE7910300L/xx unknown
- 1979-12-17 AU AU53905/79A patent/AU5390579A/en not_active Abandoned
- 1979-12-18 IT IT28170/79A patent/IT1193348B/it active
- 1979-12-19 CA CA000342263A patent/CA1149284A/en not_active Expired
- 1979-12-19 BE BE0/198657A patent/BE880744A/fr not_active IP Right Cessation
- 1979-12-19 LU LU82013A patent/LU82013A1/fr unknown
- 1979-12-19 DK DK542979A patent/DK542979A/da unknown
- 1979-12-19 FR FR7931158A patent/FR2444459A1/fr active Granted
- 1979-12-19 ES ES487052A patent/ES487052A0/es active Granted
- 1979-12-19 DE DE19792951050 patent/DE2951050A1/de not_active Withdrawn
- 1979-12-20 NL NL7909199A patent/NL7909199A/nl not_active Application Discontinuation
- 1979-12-20 ZA ZA00796918A patent/ZA796918B/xx unknown
- 1979-12-20 JP JP16495079A patent/JPS55115822A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| CA1149284A (en) | 1983-07-05 |
| JPS55115822A (en) | 1980-09-06 |
| SE7910300L (sv) | 1980-06-22 |
| AU5390579A (en) | 1980-06-26 |
| FR2444459B1 (cs) | 1983-04-01 |
| DE2951050A1 (de) | 1980-07-10 |
| JPS6328045B2 (cs) | 1988-06-07 |
| ZA796918B (en) | 1980-11-26 |
| IL58948A0 (en) | 1980-03-31 |
| GB2039736B (en) | 1983-04-13 |
| GB2039736A (en) | 1980-08-20 |
| ES8102108A1 (es) | 1980-12-16 |
| IT7928170A0 (it) | 1979-12-18 |
| BE880744A (fr) | 1980-06-19 |
| LU82013A1 (fr) | 1981-02-03 |
| FR2444459A1 (fr) | 1980-07-18 |
| ES487052A0 (es) | 1980-12-16 |
| US4384001A (en) | 1983-05-17 |
| DK542979A (da) | 1980-06-22 |
| IT1193348B (it) | 1988-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK137996A3 (en) | Cancer treatment and metastasis prevention | |
| NL7909199A (nl) | Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan. | |
| US6579891B1 (en) | Agent and method for prevention and treatment of cancer in animals | |
| US6407125B1 (en) | Pharmacological agent and method of treatment | |
| US20060074063A1 (en) | Pharmacological agent and method of treatment | |
| US6403618B1 (en) | Agent and method for controlling angiogenesis | |
| AU709620B2 (en) | New applications of lysozyme dimer | |
| DE60032915T2 (de) | Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen | |
| CN108685892B (zh) | 绿原酸及其组合物在制备治疗鳞状细胞癌的药物中的用途 | |
| CN111346081A (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
| KR20060061367A (ko) | 디파이브로타이드를 단독으로 또는 다른 항암제들과조합하여 포함하는 항암제제 | |
| Taliaferro | The Role of the Spleen and the Lymphoid-macrophage System in the Quinine Treatment of Gallinaceum Malaria: I. Acquired Immunity and Phagocytosis | |
| WO2021023291A1 (zh) | 原黄素在肺癌治疗中的应用 | |
| JPS6379824A (ja) | 制癌剤 | |
| NL9300065A (nl) | Samenstelling voor het versnellen van wondgenezing. | |
| RU2282437C1 (ru) | Средство для лечения болезней суставов | |
| CN111514290A (zh) | 一种葫芦素组合物及其用途 | |
| NL8501840A (nl) | Inhibitie van tumorontwikkeling. | |
| RU2680804C1 (ru) | Стабильное средство лечения болезней суставов | |
| CN113456643B (zh) | 一种含普那布林的药物组合及其应用 | |
| RU2119334C1 (ru) | Антгельминтное средство | |
| US20130079416A1 (en) | Homeopathic medicament comprising phenacetin for the treatment of cancer | |
| RU2681546C1 (ru) | Способ экстренной профилактики клещевого вирусного энцефалита | |
| CN118986967A (zh) | 一种肿瘤免疫治疗药物组合物及其应用 | |
| US20060240117A1 (en) | Snake powder extract for treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |